Trade GHRS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
GH Research PLC (GHRS) is trading at US$18.56, up 1.70% today as of Nov 19, 16:00 EST. The company has a market capitalisation of US$1.23B. Over the past 52 weeks, GHRS has traded between US$12.04 and US$31.44. On Syfe you can trade GHRS with $0 commission and add it to your watchlist.
| Previous close | US$18.25 |
|---|---|
| Market cap | US$1.23B |
| 52-week range | US$12.04 – US$31.44 |
| Volume | 275.95K |
| Exchange | US |
GH Research PLC
GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
Year: 2021
Wells Fargo Initiates GH Research at Overweight With $44 Price Target
Jul 27, 12:12 PM · MT Newswires
GH Research PLC (GHRS) stock is trading at US$18.56, +1.70% from the previous close of US$18.25.
The market cap for GH Research PLC (GHRS) stock is approximately US$1.23B.
The 52-week high for GH Research PLC (GHRS) stock is US$31.44.
The 52-week low for GH Research PLC (GHRS) stock is US$12.04.
GH Research PLC (GHRS) does not currently pay a dividend.
Stay on top of GHRS
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore